Felix R. Shardonofsky
Boston Children's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Felix R. Shardonofsky.
Journal of Applied Physiology | 2012
Felix R. Shardonofsky; Joan Moore; Robert J. Schwartz; Aladin M. Boriek
We hypothesized that ablation of smooth muscle α-actin (SM α-A), a contractile-cytoskeletal protein expressed in airway smooth muscle (ASM) cells, abolishes ASM shortening capacity and decreases lung stiffness. In both SM α-A knockout and wild-type (WT) mice, airway resistance (Raw) determined by the forced oscillation technique rose in response to intravenous methacholine (Mch). However, the slope of Raw (cmH(2)O·ml(-1)·s) vs. log(2) Mch dose (μg·kg(-1)·min(-1)) was lower (P = 0.007) in mutant (0.54 ± 0.14) than in WT mice (1.23 ± 0.19). RT-PCR analysis performed on lung tissues confirmed that mutant mice lacked SM α-A mRNA and showed that these mice had robust expressions of both SM γ-A mRNA and skeletal muscle (SKM) α-A mRNA, which were not expressed in WT mice, and an enhanced SM22 mRNA expression relative to that in WT mice. Compared with corresponding spontaneously breathing mice, mechanical ventilation-induced lung mechanical strain increased the expression of SM α-A mRNA in WT lungs; in mutant mice, it augmented the expressions of SM γ-A mRNA and SM22 mRNA and did not alter that of SKM α-A mRNA. In mutant mice, the expression of SM γ-A mRNA in the lung during spontaneous breathing and its enhanced expression following mechanical ventilation are consistent with the likely possibility that in the absence of SM α-A, SM γ-A underwent polymerization and interacted with smooth muscle myosin to produce ASM shortening during cholinergic stimulation. Thus our data are consistent with ASM in mutant mice experiencing compensatory mechanisms that modulated its contractile muscle capacity.
Human Mutation | 2018
Przemyslaw Szafranski; Ewelina Kośmider; Qian Liu; Justyna A. Karolak; Lauren Currie; Sandhya Parkash; Stephen G. Kahler; Elizabeth Roeder; Rebecca Okashah Littlejohn; Thomas S. DeNapoli; Felix R. Shardonofsky; Cody Lance Henderson; George Powers; Virginie Poisson; Denis Bérubé; Luc L. Oligny; Jacques L. Michaud; Sandra Janssens; Kris De Coen; Jo Van Dorpe; Annelies Dheedene; Matthew T. Harting; Matthew Weaver; Amir M. Khan; Nina Tatevian; Jennifer A. Wambach; Kathleen A. Gibbs; Edwina J. Popek; Anna Gambin; Pawel Stankiewicz
Transposable elements modify human genome by inserting into new loci or by mediating homology‐, microhomology‐, or homeology‐driven DNA recombination or repair, resulting in genomic structural variation. Alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV) is a rare lethal neonatal developmental lung disorder caused by point mutations or copy‐number variant (CNV) deletions of FOXF1 or its distant tissue‐specific enhancer. Eighty‐five percent of 45 ACDMPV‐causative CNV deletions, of which junctions have been sequenced, had at least one of their two breakpoints located in a retrotransposon, with more than half of them being Alu elements. We describe a novel ∼35 kb‐large genomic instability hotspot at 16q24.1, involving two evolutionarily young LINE‐1 (L1) elements, L1PA2 and L1PA3, flanking AluY, two AluSx, AluSx1, and AluJr elements. The occurrence of L1s at this location coincided with the branching out of the Homo‐Pan‐Gorilla clade, and was preceded by the insertion of AluSx, AluSx1, and AluJr. Our data show that, in addition to mediating recurrent CNVs, L1 and Alu retrotransposons can predispose the human genome to formation of variably sized CNVs, both of clinical and evolutionary relevance. Nonetheless, epigenetic or other genomic features of this locus might also contribute to its increased instability.
Jbjs Essential Surgical Techniques | 2015
Ajeya P. Joshi; Megan K. Roth; James W. Simmons; Felix R. Shardonofsky; Robert M. Campbell
Overview Introduction Although surgical treatment of spondylothoracic dysplasia (STD) is controversial, we have found that an expansion thoracoplasty using a Vertical Expandable Prosthetic Titanium Rib (VEPTR; DePuy Synthes) results in favorable outcomes, including 100% survivability (at an average follow-up of 6.2 years), increased thoracic spinal length, and decreased requirements for ventilation support. Step 1: Preoperative Preparation Make anteroposterior and lateral radiographs of the spine. Step 2: Position the Patient for the Procedure The patient is placed in the prone position. Step 3: The Incision A curvilinear skin incision is made, starting proximally between the spine and the medial edge of the scapula. Step 4: The Osteotomy Perform the v-osteotomy. Step 5: Placement of the VEPTR Device A number-4 VEPTR-I device is wedged in, starting laterally within the osteotomy sites, wedging the osteotomies apart, distracting the superior ribs proximally and the inferior ribs distally, lengthening the hemithorax, and stopping approximately at the posterior axillary line, when there is maximum stress on the superior and inferior ribs, to avoid fracture, and the lamina spreaders are then removed. Step 6: Wound Closure Insert drains and local anesthetic catheters and close the wound. Step 7: Expansion and Replacement Procedures Lengthen the devices with the standard VEPTR technique of limited 3-cm incisions every three to six months. Results VEPTR treatment in patients with STD is associated with increased thoracic spine height and reduced thoracic width-to-height ratio, suggesting a greater gain in height than in width. What to Watch For Indications Contraindications Pitfalls & Challenges
Proceedings of the National Academy of Sciences of the United States of America | 2004
Zsuzsanna Callaerts-Vegh; Kj Evans; Noornabi Dudekula; Donald L Cuba; Brian J. Knoll; Patrick Callaerts; Heather Giles; Felix R. Shardonofsky; Richard A. Bond
Pulmonary Pharmacology & Therapeutics | 2008
Nicola A. Hanania; Supria Singh; Rami El-Wali; Michael Flashner; Amie Franklin; William J. Garner; Burton F. Dickey; Sergio Parra; Stephen J. Ruoss; Felix R. Shardonofsky; Brian O'Connor; Clive P. Page; Richard A. Bond
Pulmonary Pharmacology & Therapeutics | 2008
Rui Lin; Hui Peng; Long P. Nguyen; Noor Dudekula; Felix R. Shardonofsky; Brian J. Knoll; Sergio Parra; Richard A. Bond
Journal of Applied Physiology | 2003
Kj Evans; Richard A. Bond; David B. Corry; Felix R. Shardonofsky
Journal of Applied Physiology | 2006
Bohao Chen; Gustine Liu; Felix R. Shardonofsky; Maria L. Dowell; Oren Lakser; Richard W. Mitchell; Jeffrey J. Fredberg; Lawrence H. Pinto; Julian Solway
American Journal of Physiology-lung Cellular and Molecular Physiology | 2006
Felix R. Shardonofsky; Yassemi Capetanaki; Aladin M. Boriek
Journal of Applied Physiology | 2001
Felix R. Shardonofsky; Todd M. Officer; Aladin M. Boriek; Joseph R. Rodarte